Skip to main content
Top
Published in: World Journal of Pediatrics 1/2023

17-10-2022 | COVID-19 Vaccination | Original Article

Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children’s medical center in Shanghai, China

Authors: Nan Shen, Yu-Fen Wu, Yi-Wei Chen, Xiao-Yan Fang, Min Zhou, Wen-Yu Wang, Ming-Yu Tang, Qiu-Hui Pan, Ji Ma, Hao Zhang, Qing Cao

Published in: World Journal of Pediatrics | Issue 1/2023

Login to get access

Abstract

Background

The number of pediatric cases of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has increased. Here, we describe the clinical characteristics of children in a tertiary children’s medical center in Shanghai.

Methods

A total of 676 pediatric coronavirus disease 2019 (COVID-19) cases caused by the Omicron variant who were admitted to the Shanghai Children's Medical Center from March 28 to April 30, 2022 were enrolled in this single-center, prospective, observational real-world study. Patient demographics and clinical characteristics, especially COVID-19 vaccine status, were assessed.

Results

Children of all ages appeared susceptible to the SARS-CoV-2 Omicron variant, with no significant difference between sexes. A high SARS-CoV-2 viral load upon admission was associated with leukocytopenia, neutropenia, and thrombocytopenia (P = 0.003, P = 0.021, and P = 0.017, respectively) but not with physical symptoms or radiographic chest abnormalities. Univariable linear regression models indicated that comorbidities (P = 0.001) were associated with a longer time until viral clearance, and increasing age (P < 0.001) and two doses of COVID-19 vaccine (P = 0.001) were associated with a shorter time to viral clearance. Multivariable analysis revealed an independent effect of comorbidities (P < 0.001) and age (P = 0.003). The interaction effect between age and comorbidity showed that the negative association between age and time to virus clearance remained significant only in patients without underlying diseases (P < 0.001).

Conclusion

This study describes the clinical characteristics of children infected with the Omicron variant of SARS-CoV-2 and calls for additional studies to evaluate the effectiveness and safety of vaccination against COVID-19 in children.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399:2011–2.CrossRef Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet. 2022;399:2011–2.CrossRef
2.
go back to reference Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30:1077–83.CrossRef Ai J, Wang X, He X, Zhao X, Zhang Y, Jiang Y, et al. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe. 2022;30:1077–83.CrossRef
3.
go back to reference Gu H, Krishnan P, Ng DYM, Chang LDJ, Liu GYZ, Cheng SSM, et al. Probable transmission of SARS-CoV-2 Omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect Dis. 2022;28:460–2.CrossRef Gu H, Krishnan P, Ng DYM, Chang LDJ, Liu GYZ, Cheng SSM, et al. Probable transmission of SARS-CoV-2 Omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect Dis. 2022;28:460–2.CrossRef
5.
go back to reference Zheng H, Cao Y, Chen X, Wang F, Hu Y, Song W, et al. Disease profile and plasma neutralizing activity of post-vaccination Omicron BA1 infection in Tianjin, China: a retrospective study. Cell Res. 2022;32:781–4.CrossRef Zheng H, Cao Y, Chen X, Wang F, Hu Y, Song W, et al. Disease profile and plasma neutralizing activity of post-vaccination Omicron BA1 infection in Tianjin, China: a retrospective study. Cell Res. 2022;32:781–4.CrossRef
6.
go back to reference Levy N, Koppel JH, Kaplan O, Yechiam H, Shahar-Nissan K, Cohen NK, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022;327:2452–4.CrossRef Levy N, Koppel JH, Kaplan O, Yechiam H, Shahar-Nissan K, Cohen NK, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022;327:2452–4.CrossRef
7.
go back to reference Xue FX, Shen KL. COVID-19 in children and the importance of COVID-19 vaccination. World J Pediatr. 2021;17:462–6.CrossRef Xue FX, Shen KL. COVID-19 in children and the importance of COVID-19 vaccination. World J Pediatr. 2021;17:462–6.CrossRef
8.
go back to reference Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94.CrossRef Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–94.CrossRef
9.
go back to reference Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386:340–50.CrossRef Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386:340–50.CrossRef
10.
go back to reference Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–9.CrossRef Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385:187–9.CrossRef
11.
go back to reference Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702.CrossRef Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145:e20200702.CrossRef
12.
go back to reference Pinninti SG, Pati S, Poole C, Latting M, Seleme MC, Yarbrough A, et al. Virological characteristics of hospitalized children with SARS-CoV-2 infection. Pediatrics. 2021;147:e2020037812.CrossRef Pinninti SG, Pati S, Poole C, Latting M, Seleme MC, Yarbrough A, et al. Virological characteristics of hospitalized children with SARS-CoV-2 infection. Pediatrics. 2021;147:e2020037812.CrossRef
13.
go back to reference Cohen CA, Li APY, Hachim A, Hui DSC, Kwan MYW, Tsang OTY, et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nat Commun. 2021;12:4678.CrossRef Cohen CA, Li APY, Hachim A, Hui DSC, Kwan MYW, Tsang OTY, et al. SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection. Nat Commun. 2021;12:4678.CrossRef
14.
go back to reference Cheung PH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022. Emerg Microbes Infect. 2022;11:1072–8.CrossRef Cheung PH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022. Emerg Microbes Infect. 2022;11:1072–8.CrossRef
15.
go back to reference Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Kim SH, et al. SARS-CoV-2 Omicron mutation is faster than the chase: multiple mutations on spike/ACE2 interaction residues. Immune Netw. 2021;21:e38.CrossRef Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Kim SH, et al. SARS-CoV-2 Omicron mutation is faster than the chase: multiple mutations on spike/ACE2 interaction residues. Immune Netw. 2021;21:e38.CrossRef
16.
go back to reference Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679–86.CrossRef Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679–86.CrossRef
18.
go back to reference Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods-United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:146–52.CrossRef Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods-United States, December 2020-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:146–52.CrossRef
19.
go back to reference Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. 2022;607:119–27.CrossRef Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. 2022;607:119–27.CrossRef
20.
go back to reference Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic features of severe acute respiratory syndrome coronavirus 2 infection in children. J Infect Dis. 2021;224:1821–9.CrossRef Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic features of severe acute respiratory syndrome coronavirus 2 infection in children. J Infect Dis. 2021;224:1821–9.CrossRef
21.
go back to reference Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532–46.CrossRef Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532–46.CrossRef
22.
go back to reference Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11:337–43.CrossRef Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022;11:337–43.CrossRef
Metadata
Title
Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children’s medical center in Shanghai, China
Authors
Nan Shen
Yu-Fen Wu
Yi-Wei Chen
Xiao-Yan Fang
Min Zhou
Wen-Yu Wang
Ming-Yu Tang
Qiu-Hui Pan
Ji Ma
Hao Zhang
Qing Cao
Publication date
17-10-2022
Publisher
Springer Nature Singapore
Published in
World Journal of Pediatrics / Issue 1/2023
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-022-00621-6

Other articles of this Issue 1/2023

World Journal of Pediatrics 1/2023 Go to the issue